A cutoff value of p16-positive tumor cells allows the separation of patients with NIL from those with IBC, so that IHC analysis of p16 expression can be used as an additional diagnostic test in separating benign from malignant changes in the breast. This evidence concerns the gene CDKN2A and inflammatory breast carcinoma.